24/7 Market News Snapshot 07 July, 2025 – Cyclacel Pharmaceuticals, Inc (NASDAQ:CYCC)
DENVER, Colo., 07 July, 2025 (www.247marketnews.com) – (NASDAQ:CYCC) are discussed in this article.
Cyclacel Pharmaceuticals, Inc. (CYCC) has seen a remarkable surge in its stock value, trading at $3.915, up 10.59% from a previous close of $3.540. This upward momentum has been highlighted by an impressive trading volume of 4.01 million shares, indicating heightened investor interest and suggesting a bullish sentiment surrounding the company. Technical indicators, including the Relative Strength Index (RSI) and moving averages, may further reinforce this trend, positioning CYCC as a stock to monitor closely in the coming sessions.
In a strategic move to bolster its market presence, Cyclacel has announced a significant amendment to its Exchange Agreement with FITTERS Diversified Berhad. The revised agreement will facilitate the exchange of all ordinary shares of FITTERS’ subsidiary, Fitters Sdn. Bhd., for common stock in Cyclacel. This transaction will result in Fitters Sdn. Bhd. becoming a wholly-owned subsidiary of Cyclacel, with Cyclacel issuing shares that represent 19.99% of its outstanding stock as of the closing date, in addition to a $1,000,000 payment to FITTERS.
The boards of both companies have unanimously approved the transaction, which awaits the endorsement of Cyclacel’s stockholders and FITTERS. This partnership is anticipated to create synergies that enhance both entities’ operational capabilities, uniting expertise in innovative safety solutions and cutting-edge cancer therapies. The amendment has also revised the closing date of the transaction to September 30, 2025, providing ample time for necessary approvals and assessments.
Cyclacel remains dedicated to advancing its clinical-stage pipeline focused on combating cancer through pioneering biopharmaceutical endeavors, while Fitters Sdn. Bhd. is recognized for its commitment to quality in the provision of essential safety products. This collaboration is poised to catalyze growth and innovation for both companies, establishing a new frontier in the industry.
Related news for (CYCC)
- Plogosertib Shows Promise in Biliary Tract Cancer with BUBR1 as Potential Biomarker
- MoBot’s Stock Market Highlights – 07/23/25 01:00 PM
- Breaking News: MoBot’s Latest Update as of 07/23/25 12:00 PM
- Breaking News: MoBot’s Latest Update as of 07/18/25 11:00 AM
- MoBot’s Stock Market Highlights – 07/18/25 10:00 AM